Skip to main content
. 2021 Dec 15;7(1):100314. doi: 10.1016/j.esmoop.2021.100314

Table 2.

Summary of responses: randomized population

Responses, n (%) Varlitinib + capecitabine (n = 64) Placebo + capecitabine (n = 63)
Objective response 6 (9.4) 3 (4.8)
 Complete response 0 (0) 0 (0)
 Partial response 6 (9.4) 3 (4.8)
Stable disease 29 (45.3) 34 (54.0)
Progressive disease 24 (37.5) 24 (38.1)
 Early death 4 (6.3) 0 (0)
 RECIST v1.1 progression 20 (31.3) 24 (38.1)
Non-evaluable 5 (7.8) 2 (3.2)